Mazdutide
Also known as: IBI362, LY3305677, GLP-1/glucagon dual agonist
strong human dataNot FDA approvedResearch only
Published Dose Range
Low3 mg/week
Typical6 mg/week
High9 mg/week
Phase 3 GLORY-1 trial in Chinese adults with obesity used 6 mg or 9 mg weekly. Dose-escalation over 4-week intervals.
Published Cycle Range
No published cycle data available.
Administration
Routessubcutaneous
FrequencyOnce weekly
Preferred timingSame day each week
Safety Profile
Contraindications
- • Personal or family history of medullary thyroid carcinoma (class label)
Common side effects
- • Nausea
- • Diarrhea
- • Vomiting
- • Decreased appetite
Serious risks
- • Pancreatitis risk (class effect)
- • Hyperglycemia in non-diabetics (glucagon component)
Drug interactions
- • Insulin
- • Sulfonylureas
Requires monitoring
- • Blood glucose
- • Heart rate
Pregnancy / breastfeeding
Avoid — limited safety data
Common Misconceptions
- Approved for obesity in China (2025) but not yet FDA-approved
- Often confused with tirzepatide — different mechanism (GLP-1/glucagon vs GLP-1/GIP)
Next Steps
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.